Article

Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infection

2024-11-13

Abstract excerpt

Hematopoietic stem/progenitor cell (HSPC)-based anti-HIV-1 gene therapy holds promise to provide life-long remission following a single treatment. Here we report a multi-pronged anti-HIV-1 HSPC-based gene therapy designed to defend against and attack HIV-1 infection. We developed a lentiviral vector capable of co-expressing three anti-HIV-1 genes. Two are designed to prevent infection, including a short-hairpin RN...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 29bac02e-340f-58d2-92ec-50e7ab74cb28
DOI: 10.1101/2024.11.13.623476

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Anti-HIV-1 HSPC-based gene therapy with safety kill switch to defend against and attack HIV-1 infectionDOI 10.1101/2024.11.13.623476Read

Combining Cell-Intrinsic and -Extrinsic Resistance to HIV-1 By Engineering Hematopoietic Stem Cells for CCR5 Knockout and B Cell Secretion of Therapeutic AntibodiesSemantic proximity Read

CRISPR/Cas9-Mediated CCR5 Ablation in Human Hematopoietic Stem/Progenitor Cells Confers HIV-1 Resistance In Vivo.Semantic proximity Read

Chimeric Antigen Receptor Engineered Stem Cells: A Novel HIV TherapySemantic proximity Read

Allogeneic gene-edited HIV-specific CAR-T cells secreting PD-1 blocking scFv enhance anti-HIV activity in vitroSemantic proximity Read

Clinical trial results provide the rationale to protect dual HIV-specific T cells with a signaling-defective HIV fusion inhibitor.Semantic proximity Read

CCR5-edited gene therapies for HIV cure: Closing the door to viral entry.Semantic proximity Read

Knowledge From London and Berlin: Finding Threads to a Functional HIV Cure.Semantic proximity Read

Engineering HIV-Resistant, Anti-HIV Chimeric Antigen Receptor T CellsSemantic proximity Read

Development of HIV-Resistant CAR T Cells by CRISPR/Cas-Mediated CAR Integration into the CCR5 LocusSemantic proximity Read

Optimizing CRISPR/Cas9 genome editing in primary human hematopoietic cells to advance studies into HIV biologySemantic proximity Read

Targeting PD-1 <sup>+</sup> T-cells with Chimeric Antigen Receptors to reduce the HIV ReservoirSemantic proximity Read

<i>In vivo</i> production of an anti-HIV antibody from primate hematopoietic cells by non-viral knock-inSemantic proximity Read